# A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Alain Townsend[1,2]*, Pramila Rijal[1,2], Julie Xiao[1], Tiong Kit Tan[1], Kuan-Ying A Huang[3], Lisa Schimanski[1,2], Jiangdong Huo[4], Nimesh Gupta[5], Rolle Rahikainen[6], Philippa C Matthews[7,8], Derrick Crook[7,9,10], Sarah Hoosdally[8,10], Teresa Street[9], Justine Rudkin[11], Nicole Stoesser[7,9], Fredrik Karpe[12], Matthew Neville[12], Rutger Ploeg[13], Marta Oliveira[13], David J Roberts[14,15], Abigail A Lamikanra[14], Hoi Pat Tsang[14], Abbie Bown[16], Richard Vipond[16], Alexander J Mentzer[17], Julian C Knight[17], Andrew Kwok[17], Gavin Screaton[17,18], Juthathip Mongkolsapaya[2,18,19], Wanwisa Dejnirattisai[17], Piyada Supasa[17], Paul Klenerman[8], Christina Dold[20,21], Kenneth Baillie[22], Shona C Moore[23], Peter JM Openshaw[24], Malcolm G Semple[23], Lance CW Turtle[25], Mark Ainsworth[26], Alice Allcock[17], Sally Beer[26], Sagida Bibi[20], Elizabeth Clutterbuck[20], Alexis Espinosa[26], Maria Mendoza[26], Dominique Georgiou[26], Teresa Lockett[26], Jose Martinez[26], Elena Perez[26], Veronica Sanchez[26], Giuseppe Scozzafava[26], Alberto Sobrinodiaz[26], Hannah Thraves[26], Etienne Joly[27]*

[1]MRC Human Immunology Unit, MRC Weatherall Institute, John Radcliffe Hospital, Oxford OX3 9DS, UK

[2]Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

[3]Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University and Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan

[4]Structural Biology, The Rosalind Franklin Institute, Harwell Science & Innovation Campus, OX11 0FA, UK

[5]Vaccine Immunology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi – 110067, India

[6]Department of Biochemistry, University of Oxford, South Park Road OX1 3QU, UK

[7]Department of Microbiology and Infectious Diseases, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK

[8]Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK

[9]Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Headley

Way, Oxford OX3 9DU, UK

[10]Oxford NIHR Biomedical Research Centre, John Radcliffe Hospital, Headley Way, Oxford OX3

9DU, UK

[11]Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford,

OX3 7LF

[12]Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of

Medicine, University of Oxford, Oxford, UK

[13]Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital,

Headington, Oxford OX3 9DU, UK

[14]NHS Blood and Transplant, John Radcliffe Hospital, Headington, Oxford OX3 9BQ, UK

[15]BRC Haematology Theme and Radcliffe Department of Medicine, University of Oxford, John

Radcliffe Hospital, Oxford, OX3 9DU

[16]Porton Down, Public Health England, Manor Farm Road, Porton Down, Salisbury, SP4 0JG,

UK

[17]Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK

[18]Division of Medical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK

[19]Dengue Hemorrhagic Fever Research Unit, Office for Research and Development, Faculty of

Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

[20]Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LE, UK

[21]NIHR Oxford Biomedical Research Centre, Centre for Clinical Vaccinology and Tropical

Medicine, University of Oxford, Oxford, UK

[22]Anaesthesia, Critical Care and Pain Medicine Division of Health Sciences, University of

Edinburgh, Edinburgh, UK

[23]NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of

Infection, Veterinary and Ecological Sciences, University of Liverpool

[24]National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London,

UK

[25]Tropical and Infectious Diseases Unit, Liverpool University Hospitals NHS Foundation Trust,

Liverpool, UK

[26]Oxford University Hospitals NHS Foundation Trust, Oxford, UK

[27]Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS,

Toulouse; France

*Corresponding Authors

Correspondence to Alain Townsend (alain.townsend@imm.ox.ac.uk) and Etienne Joly

(atnjoly@mac.com)

**ABSTRACT**

Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of

seroconversion in populations, detection of seroconversion after vaccination, and for seeking

evidence for a level of antibody that may be protective against COVID-19 disease. Several

high-performance commercial tests have been described, but these require centralised

laboratory facilities that are comparatively expensive, and therefore not available universally.

Red cell agglutination tests have a long history in blood typing, and general serology through

linkage of reporter molecules to the red cell surface. They do not require special equipment,

are read by eye, have short development times, low cost and can be applied as a Point of Care

Test (POCT). We describe a red cell agglutination test for the detection of antibodies to the

SARS-CoV-2 receptor binding domain (RBD). We show that the Haemagglutination Test

("HAT") has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR

diagnosed infection. The HAT can be titrated, detects rising titres in the first five days of

hospital admission, correlates well with a commercial test that detects antibodies to the RBD,

and can be applied as a point of care test. The developing reagent is composed of a previously

described nanobody to a conserved glycophorin A epitope on red cells, linked to the RBD from

SARS-CoV-2. It can be lyophilised for ease of shipping. We have scaled up production of this

reagent to one gram, which is sufficient for ten million tests, at a cost of ~0.27 UK pence per

test well. Aliquots of this reagent are ready to be supplied to qualified groups anywhere in

the world that need to detect antibodies to SARS-CoV-2, but do not have the facilities for high

throughput commercial tests.

**INTRODUCTION**

Red cell agglutination tests have a distinguished history. Since Landsteiner's classic

observations in 1901 (Landsteiner, 1961) (English translation), they have been used for the

determination of blood groups (Schwarz & Dorner, 2003) detection of influenza viruses (Hirst, 1941) and in a wide variety of applications championed by Prof. Robin Coombs for the detection of specific antibodies or antigens (Coombs, Mourant, & Race, 1945) (reviewed by (Pamphilon & Scott, 2007)). They have the great advantage of being simple, inexpensive, can be read by eye, and do not require sophisticated technology for their application. In the recent era the linkage of an antigen to the red cell surface has become easier with the possibility of fusing a protein antigen sequence with that of a single domain antibody or nanobody specific for a molecule on the red cell surface (discussed in (Habib et al., 2013)).

We have applied this concept to provide a simple Haemagglutination Test ("HAT") for the detection of antibodies to the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein. The RBD is a motile subdomain at the tip of the SARS-CoV-2 spike protein that is responsible for binding the virus to its ACE2 receptor. The RBD of betacoronaviruses folds independently of the rest of the spike protein (Lan et al., 2020; Li, Li, Farzan, & Harrison, 2005; Wang et al., 2020; Yan et al., 2020). This useful property provides an Achilles' heel for the virus and allows many potential applications in vaccine design (Dai et al., 2020; Mulligan et al., 2020; Tan et al., 2020; Walls et al., 2020; Yang et al., 2020; Zha et al., 2020), and serology (Amanat et al., 2020; Piccoli et al., 2020; The National SARS-CoV-2 Serology Assay Evaluation Group, 2020), see also www.gov.uk/government/publications/COVID-19-laboratory-evaluations-of-serological-assays). The majority of neutralising antibodies bind to the RBD (Barnes et al., 2020; Piccoli et al., 2020), and the level of antibody to the RBD detected in ELISA correlates with that of neutralising antibodies (Amanat et al., 2020; Piccoli et al., 2020; Robbiani et al., 2020). We reasoned therefore that a widely applicable and inexpensive test for antibodies to the RBD would be useful for research in settings where high throughput assays were not available.

In order to link the SARS-CoV-2 RBD to red cells we selected the single domain antibody (nanobody) IH4 (Habib et al., 2013), specific for a conserved epitope on glycophorin A. Glycophorin A is expressed at up to $10^6$ copies per red cell. The IH4 nanobody has previously been linked to HIV p24 to provide a monomeric reagent that bound p24 to the red cell surface. Antibodies to p24 present in serum cross-linked the p24 and agglutinated the red cells (Habib et al., 2013). We have adapted this approach to detection of antibodies to SARS-CoV-2 by

127    linking the RBD of the SARS-CoV-2 spike protein to IH4 via a short (GSG)2 linker to produce

128    the fusion protein IH4-RBD-6H (Figure 1). Since we embarked on this project, another group

129    has described preliminary results with an approach similar to ours, but using a fusion of the

130    RBD to an ScFV against the H antigen to coat red blood cells with the SARS-2 RBD (Kruse et

131    al., 2020).

**Figure 1. Haemagglutination Test (HAT) for detection of antibodies to SARS-CoV-2 Receptor**

**Binding Domain.**

A) Concept of the HAT

B) Sequence of VHH(IH4)-RBD fusion protein. Residues underlined are encoded by cloning

sites AgeI (TG) and SalI (AST). The codon optimised cDNA sequence is shown in supplementary

Information

C) SDS-PAGE gel of purified VHH(IH4)-RBD proteins. Three micrograms of protein were run on

4-12% Bolt Bis-Tris under reducing conditions. 1: IH4-RBD produced in house in Expi293F cells,

2: IH4-RBD produced by Absolute Antibody, Oxford in HEK293 cells.

## RESULTS

**Production of the IH4-RBD Reagent**

The IH4-RBD sequence (Figure 1B) was codon optimised and expressed in Expi293F cells in a standard expression vector (available on request). One advantage of this mode of production compared to bacterially produced protein as used by Habib et al, is that the reagent will carry the glycosylation moieties found in humans, which may play a role in the antigenicity of the RBD (Pinto et al., 2020). The protein (with a 6xHis tag at the C-terminus for purification) was purified by Ni-NTA chromatography which yielded ~160 mg/L. We later had one gram of the protein synthesised commercially by Absolute Antibody, Oxford. The IH4-RBD protein ran as single band at ~40 kDa on SDS PAGE (Figure 1C).

**Establishment of the Haemagglutination Test (HAT) with monoclonal antibodies to the RBD**

One purpose envisaged for the HAT is for use as an inexpensive Point of Care Test for detection of antibodies in capillary blood samples obtained by a "finger-prick". We therefore wished to employ human red cells as indicators without the need for cell separation or washes, to mimic this setting. The use of V-bottom microtiter plates to perform simplified hemagglutination tests was first described over 50 years ago (Wegmann & Smithies, 1966). In preliminary tests, we observed that 50 µL of whole blood (K2EDTA sample) diluted 1:40 in phosphate-buffered saline (PBS), placed in V-bottomed wells of a standard 96-well plate, settled in one hour to form a button of red cells at the bottom of the well. The normal haematocrit of blood is ~40% vol/vol, so this dilution provides ~1% red cells. If the plate was then tilted, the red cell button flowed to form a "teardrop" in ~30 seconds (for example Figure 2A Row 8).

If serum or plasma samples are to be tested, a standard collection of 10 mL of Type O Rh-negative (O-ve) blood into a K2EDTA tube will thus provide sufficient red cells for 8,000 test wells.

A well characterised monoclonal antibody to the RBD, CR3022 (ter Meulen et al., 2006) added to the red cells at between 0.5-32 ng/well in 50 µL, did not agglutinate the cells on its own

(Figure 2A Row 8). The addition of the IH4-RBD reagent at between 12.5-800 ng/well (in 50

µL PBS) induced a concentration dependent agglutination of the red cells, detected by the

formation of a visible mat or plug of agglutinated cells, and the loss of teardrop formation on

tilting the plate (Figure 2A). From repeated trials of this experiment we established that a

standard addition of 100 ng/well of the IH4-RBD developer (50 µL of a stock solution of 2

µg/mL in PBS) induced agglutination of 50 µL of 1:40 human red cells in the presence of as

little as 2 ng/well of the CR3022 monoclonal antibody. The standardised protocol used for the

subsequent tests were thus performed in 100 or 150 µL final volume, containing 100 ng of

the IH4-RBD developer, and 50 µL 1:40 whole blood (~1% v/v red cells ~ 0.5 µL packed red

cells per reaction). After 60 minutes incubation at room temperature, we routinely

photographed the plates after the 30 s tilt for examination and reading.

The requirement for 100 ng of the IH4-RBD developer per test well means that the gram of

IH4-RBD protein we have had synthesised is sufficient for 10 million test wells at a cost of

approximately 0.27 UK pence per test.

**Figure 2. Haemagglutination with human monoclonal antibodies or nanobodies to the**

**SARS-CoV-2 RBD**

A) Titration of IH4-RBD and monoclonal Antibody CR3022 to RBD. Doubling dilutions of

CR3022 and IH4-RBD were prepared in separate plates. 50 µL red cells (O-ve whole blood

diluted 1:40 in PBS) were added to the CR3022 plate, followed by transfer of 50 µL titrated

IH4-RBD. From this titration, 100 ng/well of IH4-RBD was chosen for detection.

B) Detection of other anti-RBD monoclonal antibodies and ACE2-Fc. Monoclonal antibodies

were prepared in doubling dilutions in 50 µL PBS from left to right, 50 µL of 1:40 O-ve red cells

were added, followed by 50 µL of IH4-RBD (2 µg/mL in PBS). The end point was defined as the

last dilution without tear drop formation on tilting the plate for ~ 30 s. The binding sites for

CR3022, EY6A and ACE2 on RBD have been defined (Huo, Zhao, et al., 2020; Lan et al., 2020;

Yan et al., 2020; Zhou et al., 2020). EW-9B and EW-9C are monoclonal antibodies against non-

RBD epitopes on the spike protein (Huang et al., 2020). ACE2-Fc has been described (Huang

et al., 2020).

Having established a standard addition of 100 ng/well of the IH4-RBD reagent, we screened a

set of twelve human monoclonal antibodies, two divalent nanobodies, and divalent ACE2-Fc,

that are known to bind to the RBD (Huang et al., 2020; Huo, Le Bas, et al., 2020; Pinto et al.,

2020; Wrapp et al., 2020; Zhou et al., 2020). These reagents bind to at least three independent

sites on the RBD, and some are strongly neutralising and capable of profound ACE2 blockade

(Huang et al., 2020; Huo, Le Bas, et al., 2020). Twelve of the 15 divalent molecules

agglutinated red cells and titrated in the HAT to an end point between 2-125 ng/well, after

addition of 100 ng IH4-RBD (Figure 2B and Supplementary Table 1). Two monoclonal

antibodies, FD-5D and EZ-7A (Huang et al., 2020) and one divalent nanobody VHH72-Fc

(Wrapp et al., 2020), failed to agglutinate red cells in the presence of the IH4-RBD reagent.

However, if a monoclonal antibody to human IgG was added to the reaction (50 μL of mouse

anti-human IgG, Sigma Clone GG5 1:100), these molecules specifically agglutinated the red

cells (Supplementary Figure 1A, B). This result, analogous to the "indirect" Coombs Test

(Coombs et al., 1945; Pamphilon & Scott, 2007), suggested that these three molecules had

bound to the RBD associated with the red cells but failed to crosslink to RBDs on neighbouring

red cells. However, these could be crosslinked by the anti IgG reagent. Monoclonal antibodies

to other regions of the spike protein (EW-9B, EW-9C and FJ-1C) failed to agglutinate red cells

(Figure 2B, Supplementary Table 1). Finally we looked at the effect of a divalent ACE2-Fc

molecule constructed by fusing the peptidase domain of ACE2 (amino acids 19-615) to the

hinge and Fc region of human IgG1 (described in (Huo, Le Bas, et al., 2020). ACE2-Fc

agglutinated red cells strongly in the presence of 100 ng/well of the IH4-RBD developer,

titrating to ~ 4 ng/well (Figure 2B rows 7,8).

In summary, these results showed that all of the known epitopes bound by characterised

monoclonal antibodies were displayed by the IH4-RBD reagent, as well as the ACE2 binding

site, and could mediate agglutination by specific antibodies, divalent nanobodies, or ACE2-Fc.

**Agglutination by plasma from donors convalescing from COVID-19**

These experiments established the conditions for detection of haemagglutination by monoclonal antibodies to the RBD, in particular the optimum concentration of IH4-RBD of 100 ng/well. We then proceeded to look for haemagglutination by characterised plasma from COVID-19 convalescent donors. In the first trial we tested eighteen plasma samples from patients with mostly mild illness, that had been characterised with a quantitative ELISA to detect antibodies to the RBD (Peng et al., 2020). For these experiments we used fresh O-ve blood (K2EDTA sample) diluted to 1:40 as a source of red cells to avoid agglutination by natural agglutinins in the plasma. Plasmas were titrated by doubling dilution from 1:20 in 50 µL, then 50 µL of 1:40 O-ve red cells were added, followed by addition of 100 ng of the IH4-RBD in 50 µL PBS. After one-hour incubation, plates were tilted for ~30 seconds, photographed and read. The titre of agglutination was assessed by complete loss of teardrop formation by the red cells, any formation of a teardrop was regarded as negative. Figure 3A shows that the HAT titre matched the RBD ELISA results. Four samples were scored as negative in both assays. The remaining results showed that in general the HAT titre increased with the ELISA end point titre. One sample gave a positive titre of 1:320 in the HAT but was negative in ELISA (indicated with an arrow). We investigated this sample with a developer composed of the IH4 nanobody without the RBD component, which revealed that agglutination was RBD dependent (not shown). This sample was also positive at 1:1123 in an ELISA for full length spike protein (not shown), which suggests that the antibodies contained in this serum recognised epitope(s) present on the RBD exposed in the HAT, but not on the RBD in the RBD-ELISA reference test (Peng et al., 2020). The highest titre detected in these samples by the HAT was 1:1280 (Figure 3B).

These preliminary results showed that the HAT could detect antibodies to the RBD in plasma samples from convalescent patients in a similar manner to an ELISA test, but were not sufficient to establish the sensitivity and specificity of the HAT.

**Figure 3. Titration of stored plasma in the agglutination assay.**

A) Eighteen plasma samples from mild cases were compared for titration in the HAT with 1:40 O-ve whole blood from a seronegative donor, and endpoint titre in an RBD ELISA (Peng et al., 2020)). Four samples were negative in both assays. The data point marked with an arrow on the graph (plasma 2 on the plate, Fig 3B) was checked with a reagent composed of IH4 without RBD and shown to be dependent on antibodies to the RBD. This sample did score positive for antibodies to full length spike in an ELISA (EPT 1:1123).

B) An example of titration: positive agglutination endpoints (loss of teardrop) are marked with a black solid-line circle, partial teardrops are marked with a dotted-line circle.

**Sensitivity and specificity of the Haemagglutination Test**

To formally assess the sensitivity and specificity of the HAT we collected a set of 98 "positive" plasma samples from donors diagnosed with COVID-19 by RT-PCR at least 28 days prior to sample collection (NHS Blood and Transplant), and 199 "negative" serum samples from healthy donors from the pre-COVID-19 era (Oxford Biobank). The samples were randomised before plating. The test wells were arranged in duplicate to contain serum/plasma at 1:40 dilution, and 1:40 O-ve red cells in 50 µL. 100 ng of IH4-RBD in 50 µL PBS was added to one well of the pair, 50 µL of PBS to the other (as a negative control). The negative control is important because in rare cases, particularly in donors who may have received blood transfusions, the sample may contain antibodies to non-ABO or Rhesus D antigens. After development, the plates were photographed, and read by two independent masked observers. Complete loss of teardrop was scored as positive, any flow in the teardrop as

negative. These rules were established before setting up the tests. Disagreements (7%

overall) were resolved by accepting the weaker interpretation – i.e. if one observer scored

positive but the other negative, the well was scored as negative. Having completed the

scoring the columns of samples were re-randomised and the test and scoring repeated.

Examples of test wells and scoring are shown in Figure 4. The red cells in the negative control

(PBS) wells formed a clear teardrop. Red cells in positive wells (indicated with a solid ring)

settled either into a mat or a button that failed to form any teardrop on tilting for 30 seconds.

Occasional wells (15 of 297) formed a "partial" teardrop (shown by a dashed ring). These were

scored as negative by prior agreement.

With these rules in place we obtained in the first run sensitivity 88%, specificity 99%, and in

the second run sensitivity 93%, specificity 99% (Figure 4). The Siemens Atellica

Chemiluminescence assay for detection of IgG antibodies to the RBD was run in parallel on

293 of these 297 samples and gave sensitivity 100%, specificity 100% for this sample set.

We decided prior to this formal assessment to score wells with partial teardrop formation as

negative, as these wells tended to give rise to disagreements between scorers and were not

very helpful. Fifteen of 297 wells gave a partial teardrop. Six of these fifteen were from PCR-

ve donors and scored negative on the Siemens assay, 9/16 were from PCR+ve donors and

were Siemens positive.  If partial teardrops were scored as positive, the sensitivity of the two

assays increased to 97% and 99% (from 88% and 93%), but specificity was reduced to 96%

and 98% (from 99%). This small loss of specificity would be unacceptable in sero-surveys

where the expected prevalence of previous SARS-CoV-2 infection was low.

**A** **Examples from screen of 297 test samples**

**B** **Operating Characteristics of the Haemagglutination Test**

98 PCR +ve Samples >=28 days post diagnosis
199 –ve samples from The Oxford Biobank Pre Covid-19

Test  PBS  Test  PBS

CR3022 200 ng +ve Control

PBS -ve Control

| 11 June | | | |
|---|---|---|---|
| **Sensitivity and Specificity Calculator** | | | |
| +VE = No Teardrop | | | |
| | HAT +VE | HAT -VE | |
| PCR +VE | 86 | 12 | 98 |
| PCR -VE | 1 | 198 | 199 |
| | 87 | 210 | 297 |
| | | | |
| Sensitivity % | 88 | | |
| Specificity % | 99 | | |
| Likelihood Ratio | 174.6 | | |
| 13 June | REPEAT | | |
| **Sensitivity and Specificity Calculator** | | | |
| +VE = No Teardrop | | | |
| | HAT +VE | HAT -VE | |
| PCR +VE | 91 | 7 | 98 |
| PCR -VE | 1 | 198 | 199 |
| | 92 | 205 | 297 |
| | | | |
| Sensitivity % | 93 | | |
| Specificity % | 99 | | |
| Likelihood Ratio | 184.8 | | |

**Figure 4. Operating characteristics of the HAT.**

A) The test set of 297 randomised plasma samples were diluted 1:40 mixed with 1:40 O-ve blood in two columns. IH4-RBD (100 ng in 50 µL) was added to the test samples, and PBS to negative control wells. The plates were incubated at room temperature for one hour to allow the red cell pellet to form, then tilted for ~30 seconds to allow a teardrop to form. Complete loss of teardrop was scored as positive agglutination (marked with a black solid-line circle). Full teardrop or partial teardrop (marked with a dotted-line circle) were scored negative. The samples in columns were re-randomised and tested for a second time two days later.

B) Contingency table showing the operating characteristics of the HAT.

**HAT in the Hospital Setting**

We next assessed the HAT in the setting of patients recently admitted to hospital (the first five days) through access to the COMBAT collection of samples (see methods). This set comprised 153 plasma samples from donors diagnosed with COVID-19 by PCR, with clinical syndromes classified as « Critical », « Severe », « Mild », and «PCR positive Health Care Workers ».  Seventy-nine control plasma samples donated in the pre-COVID-19 era were

obtained either from patients with bacterial sepsis (54 samples), or healthy volunteers (25

samples). Samples were titrated in 11 doubling dilutions of 50 μL from 1:40 – 1:40,096

(columns 1-11). Column 12 contained 50 μL PBS as a negative control. 50 μL of 1:40 O-ve

whole blood was added, followed by 50 μL of 2 μg/mL IH4-RBD (100 ng/well). In parallel, all

of the 153 samples from PCR positive donors were assessed by the Siemens Atellica

Chemiluminescence test for antibodies to the RBD of the spike protein. The HAT scores (as

the number of doubling dilutions of the sample required to reach the endpoint of complete

loss of teardrop), and representative agglutination results are shown in figure 5A. In Figure

5B the HAT scores are plotted with their related Siemens test scores.

None of the seventy-nine negative control samples scored as positive in the HAT at a dilution

of 1:40, thus providing 100% specificity in this set of samples. The HAT detected 131/153 (86%

sensitivity) of the samples from PCR-diagnosed donors within the first five days of hospital

admission, whereas the Siemens test detected 113/153 (74%). On day 5 the HAT detected

41/45 (91% sensitivity). Two samples had an endpoint greater than 11 doubling dilutions in

the HAT, and required a repeat measurement spanning two plates. These two samples

titrated to 13 doubling dilutions (1: 163,840). Unmasking the samples revealed that both were

acquired from an elderly lady with mild disease on days 3 and 5 of her admission. The range

of positive titres detected by HAT was broad: 1 to 13 doubling dilutions (1:40 – 1:163,840). A

correlation coefficient with the Siemens test could not be calculated as the latter has a ceiling

score of 10 (Figure 5B). A comparison of the two tests in a contingency table with cut-off of

1:40 (first doubling dilution) for HAT, and a score ≥ 1 for the Siemens test (as defined by the

manufacturer), showed a strong correlation between the two tests for detection of antibodies

to the RBD (P <0.0001; two-tailed Fisher's exact test, Figure 5B). Fifty-two of the 153 samples

were from 24 donors with COVID-19 from whom repeated samples were taken on days 1, 3,

or 5 of admission. The HAT detected a rise in agglutination titre over the first five days of

admission in 16/24 (67%) of these patients (Table 1). Reductions in titre were not detected.

**A Titration in HAT by doubling dilution**

Doubling Dilutions from 1:20 Plate 1

| N samples | 32 | 62 | 39 | 20 | 54 | 25 |
|---|---|---|---|---|---|---|
| N donors | 24 | 48 | 32 | | 43 | |

Donors were grouped according to clinical criteria; HCW = Front Line Health Care Workers; Sepsis = Samples with patients with Sepsis prior to Covid-19 pandemic; Healthy = Healthy volunteers prior to Covid-19; DD 1 = 1:40. Actual Titre = 20 x 2^DD.

**B**

| | HAT+ | HAT- | Total | Fraction |
|---|---|---|---|---|
| Siemans + | 111 | 2 | 113 | 0.98 |
| Siemans - | 20 | 20 | 40 | 0.50 |
| Total | 131 | 22 | 153 | 0.86 |
| Fraction | 0.85 | 0.91 | 0.74 | |

| P value and statistical significance | |
|---|---|
| Test | Fisher's exact test |
| P value | <0.0001 |
| P value summary | **** |
| One- or two-sided | Two-sided |

Comments
Of 22 Samples –ve in HAT, 10 were collected on Day 1
Of 20 samples –ve in both assays, 9/20 were collected on Day 1

**Figure 5. Titration of the set of 232 samples in the HAT**

A) The collection included 32 samples from 24 Critical patients, 62 samples from 48 Severe,

39 samples from 32 Mild, 20 single samples from health care workers (HCW), 54 samples from

43 patients with unrelated sepsis in the pre-COVID-19 era, 25 samples from healthy

unexposed controls. Median is indicated by a red line. DD: doubling dilutions.

B) Comparison to Siemens Result (anti RBD) with HAT titre by doubling dilution for 153

samples from Critical, Severe, Mild and HCW SARS-CoV-2 PCR positive donors.

These results showed that in the setting of hospital admission in the UK for suspected COVID-

19 disease, the HAT has an overall sensitivity of 86% and specificity of 100% by day five, and

frequently (67%) detected a rise in HAT titre during the first five days of admission. In this

context the HAT performed at least as well as the commercially available Siemens Atellica

Chemiluminescence assay (74%) for the detection of antibodies to the RBD of SARS-CoV-2

spike protein. Twenty samples were negative in both tests, but nine of these were taken on

day 1 of admission, which suggests that both tests have lower detection levels early in the

course of hospital admission, before the antibody response has fully developed.

The O-ve blood used as indicator for this experiment was collected into a heparin tube, and

then transferred to a K2EDTA tube. In order to be sure that the presence of heparin in the red

cells had not altered the behaviour of the test, and to confirm the robustness of the results,

we repeated the titrations on all of the 232 samples 34 days later, with fresh O-ve red cells

from a different donor collected as usual into a K2EDTA tube. The results are shown in

supplementary figures 2A-C. Specificity of the HAT remained at 100% (none of the 79 control

samples were detected as positive at 1:40). The correlation with the previous assay was

strong ($R^2$ = 0.975), and 99% of the 232 titrations were within one doubling dilution of the

matched earlier measurement. The slope of the correlation was 0.94 (95% CI 0.92-0.96),

significantly less than 1. This was due to a proportion of results titrating to one doubling

dilution lower titre. However, this had only a small impact on sensitivity (81% from 86%),

which was still an improvement on the Siemens test (74%) in this context of the first five days

of hospital admission. A rise in HAT titre in 16/24 during the first five days of admission was

confirmed.

**Table 1. Fifty-two samples from 24 donors who were sampled repeatedly during the first five days in hospital.**

| No | Case | Day 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|---|
| 1 | C2 | | | 40 | | 160 |
| 2 | C6 | | | 40 | | 80 |
| 3 | C7 | 0 | | | | 0 |
| 4 | C9 | 40 | | | | 2560 |
| 5 | C10 | 320 | | 320 | | |
| 6 | C23 | 0 | | 160 | | 640 |
| 7 | S5 | 80 | | 160 | | |
| 8 | S6 | 1280 | | 1280 | | 2560 |
| 9 | S7 | 80 | | | | 2560 |
| 10 | S12 | 640 | | 1280 | | |
| 11 | S13 | 0 | | 40 | | 320 |
| 12 | S14 | | | 640 | | 640 |
| 13 | S17 | | | 2560 | | 2560 |
| 14 | S20 | 160 | | 320 | | |
| 15 | S31 | 40 | | | | 1280 |
| 16 | S41 | 640 | | 1280 | | |
| 17 | S43 | | | 40 | | 160 |
| 18 | S48 | | | 1280 | | 2560 |
| 19 | M9 | | | 0 | | 160 |
| 20 | M11 | 0 | | 0 | | 0 |
| 21 | M13 | | | 0 | | 0 |
| 22 | M14 | | | 163840 | | 163840 |
| 23 | M25 | 40 | | | | 640 |
| 24 | M30 | | | 320 | | 320 |

C: Critical, S: Severe, M: Mild

**HAT as a Point of Care Test on Capillary Samples**

The HAT is designed to detect antibodies to the RBD starting at a serum dilution of 1:40, and we have found that that 50 µL of 1:40 dilution of whole blood provides an optimal concentration of red blood cells for detection by agglutination in V-bottomed 96 well plates. We have not completed an extensive analysis of the HAT as a Point of Care Test. However, we have preliminary evidence that lyophilised IH4-RBD sent to the National Institute of Immunology, New Delhi, functions as a Point of Care Test on capillary blood obtained by

finger-prick. In Figure 6, three positive (donors 1, 2 and 3) and three negative (donors 4, 5 and

6) HAT results are compared to a standard ELISA for detection of antibodies to the RBD.

**Figure 6. HAT as a point of care test.**

Capillary blood samples were obtained by lancet. Antibodies to the RBD were detected by

HAT on autologous red cells in the sample in "Test" wells (plasma at 1:40) after addition of

100 ng/well IH4-RBD (see methods). NC, Negative Control (PBS replaces IH4-RBD); PC Postive

Control (20 ng/well CR3022, an anti-RBD monoclonal antibody added). In parallel, after

removal of red cells, the plasma was tested in a standard ELISA for detection of antibodies to

the RBD. Low levels of antibody detected in the ELISA were sufficient to give a positive result

in the HAT.

Further work is needed to establish the operating characteristics of the HAT as a Point of Care

Test on capillary samples. We provide a suggested operating procedure for capillary samples

in methods.

**Distribution of the IH4-RBD as lyophilised protein**

In order to ship the IH4-RBD reagent efficiently we have examined the effects of lyophilisation

and reconstitution with water. IH4-RBD synthesised for the purpose of distribution was

provided at 5 mg/mL in PBS by Absolute Antibody Ltd, Oxford. Two hundred microlitre

aliquots (1 mg, enough for 10,000 test wells) were lyophilised overnight and stored at -20 °C.

Aliquots were thawed, reconstituted with 1 ml double distilled water and titrated against the

pre-lyophilisation material. No change in the titration occurred. We have synthesised one

gram of IH4-RBD, sufficient for 10 million test wells. This is available free of charge for any

qualified group anywhere in the world in aliquots of 1 mg (20,000 test wells).

**DISCUSSION**

The COVID-19 pandemic has had a particularly gruelling influence on the world economy, and

on most populations of the world. The appearance of such a new highly contagious virus will

probably not be a unique occurrence in the decades ahead. One of the lessons learned is the

importance of developing affordable serological tests for detection of immune responses to

SARS-CoV-2. Commercial antibody tests are not widely available to low- and middle-income

countries, and lateral flow assays, while offering early promise as a near-patient test, have

failed to deliver in terms of performance metrics, are expensive, and there are concerns about

significant batch-to-batch variation (Adams et al., 2020). By contrast, the advantages of the

HAT are the low cost of production of its single reagent (~0.27 UK pence per test well), better

performance than most lateral flow devices (Adams et al., 2020), and versatility in not

requiring anything other than a source of O-ve blood (10 mL of K2EDTA blood provides

enough for 8,000 tests), an adjustable pipette, PBS, and a standard 96 well V-bottomed plate.

We have demonstrated that the HAT functions as a viable test for the presence of antibodies

to the RBD of the SARS-CoV-2 spike protein in stored serum/plasma samples, using O-ve red

cells as indicators. In the formal assessment of sensitivity and specificity we recorded an

average 90% sensitivity and 99% specificity (Likelihood Ratio ~175), compared to 100%

sensitivity and 100% specificity for the Siemens Atellica Chemiluminescence test on the same

set of samples. The "positive" samples were selected to have been taken at least 28 days after

a positive PCR test. These conditions are optimal for serological tests by allowing time for a

rise in antibodies. The sensitivity of ~90%  and specificity of 99% did not reach the level of

98% for both recommended by the UK MHRA (The National SARS-CoV-2 Serology Assay

Evaluation Group, 2020), or 99.5% for both recommended by the Infectious Disease Society

of America (Hanson et al., 2020). However, these values are still consistent with a useful test

in appropriate contexts, provided that users are fully aware of the operating characteristics

and interpret the results correctly.

The sensitivity of the single point HAT can be enhanced (to ~98%) if wells with partial teardrop

formation are scored as positive. However, this improvement in sensitivity is gained at the

expense of a reduced specificity (to ~97%). If partial teardrops are to be scored as positive in

the spot test at 1:40, we recommend obtaining confirmation for these by ELISA. Improvement

in the operating characteristics of the HAT may be possible by a systematic analysis of buffer

composition and experimental conditions, and is being investigated. We have deliberately

kept complexity to a minimum, and thus all dilutions were made in standard PBS, and for the

moment we recommend scoring wells with partial teardrop formation as negative.

It is interesting that the HAT titrations actually performed a little better than the Siemens test

on 153 stored plasma samples from donors during the first five days of their hospital

admission (note that symptom onset may have been several days earlier), in whom it

detected 86% (81% in the repeat) of samples from PCR-diagnosed donors, compared to 74%

for the Siemens test, and gave 100% specificity for the sample set containing control plasma

from patients with sepsis and healthy controls. We speculate that at this early period of the

COVID-19 illness the immune response may be dominated by IgM that would be expected to

be particularly efficient at crosslinking the IH4-RBD labelled red cells. In addition, of the

twenty-four donors who were tested more than once in the first five days in hospital, the HAT

detected a rise in titre in sixteen (67%). A fixed high titre was detected in a further four to

provide a sensitivity of 83% in these twenty-four cases. In situations of high clinical suspicion,

the HAT could potentially have a place as a helpful test to support the diagnosis of COVID-19

by detecting a rising titre of antibodies to the RBD during hospital admission. In patients with

a prior probability of a diagnosis of COVID-19 of ~10%, the likelihood ratio of ~175 for the HAT

provides a posterior probability of ~95% for this diagnosis. However, it is essential that if

clinicians use a rising titre in the HAT as a diagnostic aid, they should be aware of the relatively

low sensitivity (~67%) in this context.

With a specificity of 99%, the HAT could be employed for epidemiological surveys of the

seropositive rate in stored serum/plasma samples from populations with a moderate

expected prevalence ~10%, which would entail a negative predictive value of ~90%. The HAT

may be useful to detect seroconversion after vaccination, and for the identification of

potential donors of high titre plasma for therapy, if the clinical trials that are in progress

demonstrate a benefit. In the absence of knowledge about the level of antibody that indicates

protection, the HAT should not be used to provide personal results to individuals, as discussed

by the UK Royal College of Pathologists (https://www.rcpath.org/profession/on-the-

agenda/COVID-19-testing-a-national-strategy.html).  Finally, we show that the lyophilised

IH4-RBD reagent sent to New Delhi functioned as expected in preliminary point of care testing

on capillary samples obtained by finger-prick. However, additional evidence is needed to

show that the sensitivity and specificity of the HAT, applied as a Point of Care Test in this way,

are comparable to the tests on stored plasma samples, as stressed by the IDSA guideline on

serological testing (Hanson et al., 2020). This will need to be done in field conditions, which is

planned.

The technique required for applying the HAT can be learned in a day by a trained laboratory

technician, paramedic, nurse or doctor. We have produced one gram of the developing IH4-

RBD reagent (enough for ten million test wells) and offer to ship lyophilised aliquots of this

material (sufficient for 10,000 tests) anywhere in the world, free of charge, for use as a

research reagent for serological studies of COVID-19.

**METHODS**

**Sample Collection and Ethics**

**Figures 1,2:** Control whole blood (K2EDTA) as a source of red cells was collected from a

healthy donor after informed consent.

**Figure 3:** Pre-pandemic negative controls: these samples were collected from healthy adults

in the Oxfordshire region of the UK between 2014 and 2016, ethics approval: Oxfordshire

Clinical Research Ethics Committee 08/H0606/107+5. Positive sample set: these were

convalescent plasma donors recruited by NHS Blood and Transplant (NHSBT), ethics approval

(NHSBT; RECOVERY [Cambridge East REC (ref: 20/EE/0101)] and REMAP-CAP [EudraCT 2015-

002340-14] studies).

**Figures 4, 5 and Table 1:** Known COVID-19 positive samples were collated from three ethically

approved studies: Gastro-intestinal illness in Oxford: COVID substudy [Sheffield REC,

reference: 16/YH/0247]ISARIC/WHO, Clinical Characterisation Protocol for Severe Emerging

Infections [Oxford REC C, reference 13/SC/0149], the Sepsis Immunomics project [Oxford REC

C, reference:19/SC/0296]) and by the Scotland A Research Ethics Committee (Ref:

20/SS/0028). Patients were recruited from the John Radcliffe Hospital in Oxford, UK, between

March and May 2020 by identification of patients hospitalised during the SARS-COV-2

pandemic and recruited into the Sepsis Immunomics and ISARIC Clinical Characterisation

Protocols. Time between onset of symptoms and sampling were known for all patients and if

labelled as convalescent patients were sampled at least 28 days from the start of their

symptoms. Written informed consent was obtained from all patients. All patients were

confirmed to have a test positive for SARS-CoV-2 using reverse transcriptase polymerase

chain reaction (RT-PCR) from an upper respiratory tract (nose/throat) swab tested in

accredited laboratories. The degree of severity was identified as mild, severe or critical

infection according to recommendations from the World Health Organisation. Severe

infection was defined as COVID-19 confirmed patients with one of the following conditions:

respiratory distress with RR>30/min; blood oxygen saturation<93%; arterial oxygen partial

pressure (PaO2) / fraction of inspired O2 (FiO2) <300 mmHg; and critical infection was defined

as respiratory failure requiring mechanical ventilation or shock; or other organ failures

requiring admission to ICU. Comparator samples from healthcare workers with confirmed

SARS-CoV-2 infection who all had mild non-hospitalised disease were collected under the

Gastro-intestinal illness in Oxford: COVID sub-study, and samples from patients with

equivalently severe disease from non-COVID infection were available from the Sepsis

Immunomics study where patients presenting with significantly abnormal physiological

markers in the pre-pandemic timeframe had samples collected using the same methodology

as that applied during the COVID pandemic. Blood samples were collected in K2EDTA

vacutainers and PBMCs were separated from plasma using Sepmate isolation tubes

(STEMCELL Technologies) and plasma was used in the downstream HAT assay.

**Figure 6:** Capillary samples were collected from members of institute staff with informed

consent (New Delhi, India). The study is a part of the COVID-19 project 'IPA/2020/000077'.

The project has been approved by the Institutional Human Ethics Committee; Ref. no. -

IHEC#128/20.

**Cloning, Expression and Purification of VHH(IH4)-RBD**

The codon-optimised gene encoding IH4-RBD sequence (Figure 1B and supplementary for the cDNA sequence) was synthesized by Integrated DNA Technologies. The gene was cloned in to the AbVec plasmid (Genbank FJ475055) using the restriction sites AgeI and HindIII (the vector supplied the signal sequence). **This expression plasmid for IH4-RBD is available on request.** Protein was expressed in Expi293F$^{TM}$ cells using the manufacturer's protocol (Thermo Fisher). Protein supernatant was harvested on day 5/6 after transfection, spun and 0.22 μm filtered. The protein was affinity-purified using a His-Trap HP column (Cytiva). Binding buffer consisted of 20 mM Sodium Phosphate, 150 mM NaCl and 20 mM Imidazole at pH 7.4, and the elution buffer of 500 mM Imidazole in 1 x binding buffer. Protein was concentrated using 15 ml Vivaspin 30 kDa MWCO filter and then buffer exchanged to PBS using a 10 ml 7 kDa Zebaspin column (Thermo Fisher).

For large scale production, the protein was synthesized by Absolute Antibody Ltd, Oxford using the same plasmid construct in HEK293 cells.

**Lyophilisation of IH4-RBD and CR3022 monoclonal antibody**

For lyophilisation, 200 μL (1 mg) of IH4-RBD (5 mg/mL) and 100 μL (200 μg) CR3022 mAb (2 mg/mL) in PBS buffer prepared in Protein Lo-Bind microcentrifuge tube (Fisher Scientific) were frozen at -80 °C and further cooled down to - 196 °C using liquid nitrogen. Pre-cooled samples were transferred to Benchtop K freeze-dryer (VirTis) with chamber at 49 μbar and condenser pre-cooled to -72.5 °C. The samples were freeze-dried for a minimum of 24 h, wrapped in Parafilm (Merck) and stored at -20 °C. Lyophilised sample was reconstituted in the same original volume of MilliQ water.

**Indirect ELISA to detect SARS-CoV-2 specific IgG (Figure 6)**

A standard indirect ELISA was used to determine the SARS-CoV-2 specific IgG levels in plasma samples. A highly purified RBD protein from SARS-CoV-2 Wuhan strain (NR-52306, BEI Resources, USA), expressed in mammalian cells, was used to capture IgG in the plasma samples. Briefly, ELISA plates (Nunc, Maxisorp) were coated with 100 μL/well of RBD antigen diluted in PBS (pH 7.4) at the final concentration of 1 μg/mL and incubated overnight at 4°C. Plates were washed three times with washing buffer (0.05% Tween-20 in PBS) followed by

the incubation with blocking buffer (3% Skim milk and 0.05% Tween-20 in PBS). The 3-fold serially diluted heat inactivated plasma samples in dilution buffer (1% Skim milk and 0.05% Tween-20 in PBS) were added into the respective wells, followed by incubation at room temperature for 1 hour. After incubation, plates were washed, and anti-human IgG conjugated with Horseradish Peroxidase (HRP) (Southern Biotech) was added in each well. After 1 h incubation, plates were washed and developed by OPD-substrate (Sigma-Aldrich) in dark at room temperature. The reaction was stopped using 2N HCl and the optical density (OD) was measured at 492 nm. The RBD-antigen coated wells that were added with sample diluent alone were used as the blank. The OD values from sample wells were plotted after subtracting the mean of OD values obtained in the blank wells.

**Equipment and Reagents for HAT**

- O-ve blood as a source of red cells collected in K2EDTA tube, diluted **in PBS to 1:20 or 1:40 as needed.** Resuspend by inverting gently ~12 times.
- BD Contact Activated Lancet Cat. No. 366594 (2 mm x 1.5 mm)
- 100 µL, 20 µL pipettes, Multichannel pipettes
- V-bottomed 96-well plates (Greiner Bio-One, Cat. No. 651101, Microplate 96-well, PS, V-bottom, Clear, 10 pieces/bag)
- Eppendorf Tubes
- K2EDTA solution (add 5 mL PBS to 10 mL K2EDTA blood collection tube = 3.6 mg K2EDTA/mL, store at 4 °C)
- Phosphate Buffered Saline Tablets (OXOID Cat. No. BR0014G)
- IH4-RBD Reagent diluted 2 µg/mL in PBS. This remains active for at least 1-2 weeks stored at 4 °C
- V-bottomed 96-well plates, numbered, dated, timed (helps when timing many plates)
- Positive control monoclonal antibody CR3022 diluted to 2 µg/mL in PBS

**Other Reagents**

Monoclonal antibody to human IgG (Gamma chain specific) Clone GG-5 Sigma Cat. No. I5885

**1. Spot test on Stored Serum/Plasma samples (Figure 4).**

1.  Plate out 50 µL of **1:20** serum/plasma in alternate columns 1,3,5,7,9,11 (add 2.5 µL sample to 47.5 µL PBS).

2.  Add 50 µL **1:20** O-ve blood collected in (**so that now sample is diluted to 1:40 and red cells at ~1% v/v**)

3.  Mix and transfer 50/100 µL to neighbouring columns 2,4,6,8,10,12 for -ve controls. The negative control is important because in rare cases, particularly in donors who have received blood transfusions, the sample in principle may contain antibodies to non-ABO or Rhesus D antigens.

4.  Add 50 µL IH4-RBD reagent (2 µg/mL in PBS = 100 ng/well) to Columns 1,3,5,7,9,11

5.  Add 50 µL PBS to columns 2,4,6,8,10,12.

6.  Inc 1 hr RT

7.  Tilt for 30 seconds

8.  Photograph: with mobile phone use the zoom function to obtain a complete field

9.  Read as Positive = No teardrop, Negative <1:40 = partial teardrop, Neg = complete teardrop.

10. Two readers should read the plates independently, and disagreements resolved by taking the lesser reading.

11. For each batch of samples set up positive control wells containing 20-100 ng monoclonal antibody CR3022 (as in Finger-Prick test below). This establishes that all of the reagents are working.

**2. Titration of Stored Serum/Plasma Samples.**

1.  Dilute samples to **1:20** in 50 µL PBS (2.5 µL to 47.5 µL) in V-bottomed plate in Rows A-H, column 1.

2.  Prepare doubling dilutions with PBS across the plate columns 1-11 (1:40 to 1:40,960), PBS control in column 12. Eight samples can be titrated per 96-well plate.

3.  Add 50 µL 1:40 O-ve red cells (1% v/v or 1:40 fresh EDTA O-ve blood sample) to all wells

4.  Add 50 µL IH4-RBD (2 µg/mL, = 100 ng/well). [Note: the red cells and IH4-RBD can be pre-mixed and added together in either 50 µL or 100 µL volume, to save a step. This variation in technique does not alter the measured titres.]

5.  Allow red cells to settle for 1 hr

6. Tilt plate for at least 30 s and photograph. The titre is defined by the last well in which the tear drop fails to form. Partial teardrop regarded as negative.

**3. Finger-prick test on capillary blood as a Point of Care Test**

1. Preparation: Clean Hands, warm digit. Prepare a plate (96-well V-bottomed) labelled with Date and Time.

2. Prick skin on outer finger pulp with disposable, single use BD or another Lancet.

3. Wipe away first drop of blood with sterile towel/swab

4. Massage second drop

5. Take a minimum of 5 µL blood with 20 µL pipette, mix immediately into 20 µL K2EDTA (3.6 mg/mL/PBS) in Eppendorf. If possible, take 20 µL of blood and mix into 80 µL K2EDTA solution. Another approach is collection of blood drops into a BD Microtainer K2E EDTA lavender vials that take 250-500 µL.

6. For 5 µL sample dilute to 200 µL with PBS (add 175 µL PBS), for 20 µL sample dilute to 800 µL (add 700 µL PBS). *Sample is now at 1:40, and the red cells are at the correct density (~1% v/v assuming a haematocrit of 40%) to give a clear tear drop.*

7. Plate 50 µL x 3 in V bottomed microtitre wells labelled T (Test), + (PC, positive Control), - (NC, negative control) – see figure 6.

8. Add 10 µL of control anti RBD Mab CR3022 (2 µg/mL stock in PBS, 20 ng/well) to "+" well

9. Add 50 µL IH4-RBD (2 µg/mL in PBS) to "T" (Test) and "+ve" wells, 50 µL PBS to "-ve" well.

10. Incubate 1 hour at RT for Red Cells to form a pellet in the "-ve" well

11. Tilt plate against a well-lit white background for ~30 seconds to allow Tear drop to form in "-ve" well.

12. The presence of antibodies to RBD is shown by loss of Tear Drop formation in the "T" and  "+ve" wells. Occasionally a partial tear drop forms – these wells are counted as Negative.

13. **Photograph the plate to record the results with the date and time**. Results can be reviewed and tabulated later. Taking picture from a distance and using the zoom function helps to take a clear picture of all wells in a 96-well plate.

14. The negative (PBS) control should be done on every sample for comparison. The
Positive control induced by CR3022 is used to check that all the reagents are working,
and that the glycophorin epitope recognised by VHH(IH4) is present on the red cells.
Absence of the IH4 epitope should be *very rare* (Habib et al., 2013)*.* For setting up
cohorts a positive control on every sample is therefore not necessary but should be
included in every *batch* of samples.

15. If a 20 µL sample of blood was taken from the finger prick there should be 650 µL of
the 1:40 diluted blood left. The red cells can be removed and a preparation of 1:40 O-
ve red cells used as above to titrate the sample. In principle the autologous red cells
could be washed repeatedly, resuspended in the same volume of PBS, and used as
indicators for the titration, however we have not attempted to do this. The s/n is 1:40
plasma that can be used in confirmatory ELISA or other tests.

**Author Contributions**

**Conceived, initiated and followed the project, documented portability and robustness of**
**HAT method in a separate laboratory, recruited collaborators:** Etienne Joly.

**Designed and produced the IH4-RBD reagent, established conditions for lyophilisation,**
**isolated and expanded human monoclonal antibodies to the RBD and ACE2-Fc, performed**
**the standard HAT assays, wrote the paper:** Alain Townsend, Pramila Rijal, Julie Xiao, Tiong
Kit Tan, Lisa Schimanski, Jiangdong Huo, Rolle Rahikainen, Kuan-Ying A Huang.

**Contributed examples of HAT as a Point of Care Test:** Nimesh Gupta.

**Provision of Serum/Plasma Sample Sets for Figure 4: Project management for Oxford**
**serology work for sensitivity and specificity measurement, assessment of preliminary data:**
Philippa Matthews, Derrick Crook, Sarah Hoosdally, Nicole Stoesser; **collection and**
**processing of samples, coordination of sample banks and running Siemens assay, ethics,**
**storage of pre-pandemic samples, coordination of provision of pre-pandemic samples from**
**Oxford BioBank, and sero-positive donors through NHSBT :** Teresa Street, Justine Rudkin,
Fredrik Karpe, Matthew Neville, Rutger Ploeg, David J Roberts, Abbie Bown, Richard Vipond,
Marta Oliveira, Abigail A Lamikanra, Hoi Pat Tsang.

**Provision of Serum Sample Sets for Figure 5 and Table 1 (COMBAT samples):** Alexander J
Mentzer, Julian C Knight, Andrew Kwok, Paul Klenerman, Christina Dold; **ISARIC4C**
**Investigators:** J. Kenneth Baillie, Shona C Moore, Peter JM Openshaw, Malcolm G Semple,

Lance CW Turtle; **Oxford Immunology Network Covid-19 Response Clinical Sample Collection Consortium:** Mark Ainsworth, Alice Allcock, Sally Beer, Sagida Bibi, Elizabeth Clutterbuck, Alexis Espinosa, Maria Mendoza, Dominique Georgiou, Teresa Lockett, Jose Martinez, Elena Perez, Veronica Sanchez, Giuseppe Scozzafava, Alberto Sobrinodiaz, Hannah Thraves.

**ACKNOWLEDGEMENT AND FUNDING**

A.T. is funded by the Medical Research Council (MR/P021336/1), Townsend-Jeantet Charitable Trust (charity number 1011770) and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002). N.G. is funded by the Science Engineering Research Board, Department of Science and Technology, India. P.C.M. is funded by the Wellcome Trust (grant ref 110110Z/15/Z). D.R. is supported by NIHR Oxford Biomedical Research Centre. National Institute for Health Research Biomedical Research Centre Funding Scheme (to G.R.S.), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002). G.R.S. is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z).

The Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2 Wuhan-Hu-1 (Figure 6), Recombinant from HEK293 Cells, NR-52306 was produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH.

We thank the healthy volunteers who kindly donated their O-ve red cells for titration of samples.

**DECLARATION**

Competing Interests none.

The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England'.

**REFERENCES**

Adams, Emily R., Ainsworth, Mark, Anand, Rekha, Andersson, Monique I., Auckland, Kathryn, Baillie,
J. Kenneth, . . . Whitehouse, James. (2020). Antibody testing for COVID-19: A report from
the National COVID Scientific Advisory Panel. *Wellcome Open Research, 5.*
doi:10.12688/wellcomeopenres.15927.1

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., . . .
Krammer, F. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat*
*Med, 26*(7), 1033-1036. doi:10.1038/s41591-020-0913-5

Barnes, C. O., West, A. P., Jr., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., .
. . Bjorkman, P. J. (2020). Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal
Common Epitopes and Recurrent Features of Antibodies. *Cell, 182*(4), 828-842 e816.
doi:10.1016/j.cell.2020.06.025

Coombs, R. R., Mourant, A. E., & Race, R. R. (1945). A new test for the detection of weak and
incomplete Rh agglutinins. *Br J Exp Pathol, 26*, 255-266.

Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., . . . Gao, G. F. (2020). A Universal Design of
Betacoronavirus Vaccines against COVID-19, MERS, and SARS. *Cell, 182*(3), 722-733 e711.
doi:10.1016/j.cell.2020.06.035

Habib, I., Smolarek, D., Hattab, C., Grodecka, M., Hassanzadeh-Ghassabeh, G., Muyldermans, S., . . .
Bertrand, O. (2013). V(H)H (nanobody) directed against human glycophorin A: a tool for
autologous red cell agglutination assays. *Anal Biochem, 438*(1), 82-89.
doi:10.1016/j.ab.2013.03.020

Hanson, K. E., Caliendo, A. M., Arias, C. A., Englund, J. A., Hayden, M. K., Lee, M. J., . . . Mustafa, R. A.
(2020). Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-
19:Serologic Testing. *Clin Infect Dis*. doi:10.1093/cid/ciaa1343

Hirst, G. K. (1941). The Agglutination of Red Cells by Allantoic Fluid of Chick Embryos Infected with
Influenza Virus. *Science, 94*(2427), 22-23. doi:10.1126/science.94.2427.22

Huang, Kuan-Ying A., Tan, Tiong Kit, Chen, Ting-Hua, Huang, Chung-Guei, Harvey, Ruth, Hussain, Saira,
. . . Townsend, Alain R. (2020). Plasmablast-derived antibody response to acute SARS-CoV-2
infection in humans. *bioRxiv*. doi:10.1101/2020.08.28.267526

Huo, J., Le Bas, A., Ruza, R. R., Duyvesteyn, H. M. E., Mikolajek, H., Malinauskas, T., . . . Naismith, J. H.
(2020). Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
*Nat Struct Mol Biol, 27*(9), 846-854. doi:10.1038/s41594-020-0469-6

Huo, J., Zhao, Y., Ren, J., Zhou, D., Duyvesteyn, H. M. E., Ginn, H. M., . . . Stuart, D. I. (2020).
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host Microbe, 28*(3),
497. doi:10.1016/j.chom.2020.07.002

Kruse, Robert L., Huang, Yuting, Smetana, Heather, Gehrie, Eric A., Amukele, Tim K., Tobian, Aaron A.
R., . . . Wang, Zack Z. (2020). A rapid, point of care red blood cell agglutination assay for
detecting antibodies against SARS-CoV-2. *bioRxiv*. doi:10.1101/2020.05.13.094490

Lan, Jun, Ge, Jiwan, Yu, Jinfang, Shan, Sisi, Zhou, Huan, Fan, Shilong, . . . Wang, Xinquan. (2020). Crystal
structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor.
*bioRxiv*. doi:10.1101/2020.02.19.956235

Landsteiner, K. (1961). On agglutination of normal human blood. *Transfusion, 1*, 5-8.
doi:10.1111/j.1537-2995.1961.tb00005.x

Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005). Structure of SARS coronavirus spike receptor-binding
domain complexed with receptor. *Science, 309*(5742), 1864-1868.
doi:10.1126/science.1116480

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., . . . Jansen, K. U. (2020).
Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature*. doi:10.1038/s41586-
020-2639-4

Pamphilon, D. H., & Scott, M. L. (2007). Robin Coombs: his life and contribution to haematology and
transfusion medicine. *Br J Haematol, 137*(5), 401-408. doi:10.1111/j.1365-2141.2007.06531.x

Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., . . . Dong, T. (2020). Broad and strong memory
CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following
COVID-19. *Nat Immunol*. doi:10.1038/s41590-020-0782-6

Piccoli, Luca, Park, Young-Jun, Tortorici, M. Alejandra, Czudnochowski, Nadine, Walls, Alexandra C.,
Beltramello, Martina, . . . Veesler, David. (2020). Mapping neutralizing and immunodominant
sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution
serology. *Cell*. doi:10.1016/j.cell.2020.09.037

Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., . . . Corti, D. (2020). Cross-
neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature, 583*(7815),
290-295. doi:10.1038/s41586-020-2349-y

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., . . . Nussenzweig, M. C.
(2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature,
584*(7821), 437-442. doi:10.1038/s41586-020-2456-9

Schwarz, H. P., & Dorner, F. (2003). Karl Landsteiner and his major contributions to haematology. *Br J
Haematol, 121*(4), 556-565. doi:10.1046/j.1365-2141.2003.04295.x

Tan, Tiong Kit, Rijal, Pramila, Rahikainen, Rolle, Keeble, Anthony H., Schimanski, Lisa, Hussain, Saira, .
. . Townsend, Alain R. (2020). COVID-19 vaccine candidate using SpyCatcher multimerization

of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising

antibody responses. *bioRxiv*. doi:10.1101/2020.08.31.275701

ter Meulen, J., van den Brink, E. N., Poon, L. L., Marissen, W. E., Leung, C. S., Cox, F., . . . Goudsmit, J.

(2006). Human monoclonal antibody combination against SARS coronavirus: synergy and

coverage of escape mutants. *PLoS Med, 3*(7), e237. doi:10.1371/journal.pmed.0030237

The National SARS-CoV-2 Serology Assay Evaluation Group, The National SARS-CoV-2 Serology Assay

Evaluation Group. (2020). *Manuscript preprint: Head-to-head benchmark evaluation of the*

*sensitivity and specificity of five immunoassays for SARS-CoV-2 serology on >1500 samples*.

Walls, A. C., Fiala, B., Schafer, A., Wrenn, S., Pham, M. N., Murphy, M., . . . King, N. P. (2020). Elicitation

of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-

CoV-2. *bioRxiv*. doi:10.1101/2020.08.11.247395

Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., . . . Qi, J. (2020). Structural and Functional Basis

of SARS-CoV-2 Entry by Using Human ACE2. *Cell, 181*(4), 894-904 e899.

doi:10.1016/j.cell.2020.03.045

Wegmann, T. G., & Smithies, O. (1966). A Simple Hemagglutination System Requiring Small Amounts

of Red Cells and Antibodies. *Transfusion*.

Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., . . . McLellan, J. S.

(2020). Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain

Camelid Antibodies. *Cell, 181*(6), 1436-1441. doi:10.1016/j.cell.2020.05.047

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020). Structural basis for the recognition of SARS-

CoV-2 by full-length human ACE2. *Science, 367*(6485), 1444-1448.

doi:10.1126/science.abb2762

Yang, J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., . . . Wei, X. (2020). A vaccine targeting the RBD of

the S protein of SARS-CoV-2 induces protective immunity. *Nature*. doi:10.1038/s41586-020-

2599-8

Zha, Lisha, Zhao, Hongxin, Mohsen, Mona O., Hong, Liang, Zhou, Yuhang, Li, Zehua, . . . Wang, Junfeng.

(2020). Development of a COVID-19 vaccine based on the receptor binding domain displayed

on virus-like particles. *bioRxiv*. doi:10.1101/2020.05.06.079830

Zhou, D., Duyvesteyn, H. M. E., Chen, C. P., Huang, C. G., Chen, T. H., Shih, S. R., . . . Huang, K. A. (2020).

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent

patient. *Nat Struct Mol Biol*. doi:10.1038/s41594-020-0480-y

 **SUPPLEMENTARY DATA**

854 Supplementary Table 1. Fifteen human monoclonal antibodies or nanobodies with endpoint

855 titres for detection in the HA Test. One divalent nanobody VHH72-Fc and two monoclonal

856 antibodies FD-5D and EZ-7A specific for the RBD failed to agglutinate red cells with the IH4-

857 RBD reagent. Three monoclonal antibodies to other regions of the spike protein EW-8B, EW-

858 9C and FJ-1C acted as negative controls.

| Mab or divalent Nanobody | HAT endpoint titre (ng/well) | Reference |
|---|---|---|
| CR3022 | 2 | (Huo, Zhao, et al., 2020; ter Meulen et al., 2006) |
| EY-6A | 16 | (Zhou et al., 2020) |
| VHH-72-Fc | Negative | (Wrapp et al., 2020) |
| FI-4A | 16 | (Huang et al., 2020) |
| ACE2-Fc | 4 | (Huo, Le Bas, et al., 2020) |
| FI-3A | 8 | (Huang et al., 2020) |
| FI-1C | 4 | (Huang et al., 2020) |
| H11-H4-Fc | 16 | (Huo, Le Bas, et al., 2020) |
| FD-5D | Negative | (Huang et al., 2020) |
| FD-11A | 31 | (Huang et al., 2020) |
| FN-12A | 31 | (Huang et al., 2020) |
| FJ-10B | 62 | (Huang et al., 2020) |
| FM-7B | 62 | (Huang et al., 2020) |
| EZ-7A | Negative | (Huang et al., 2020) |
| S309 | 125 | (Pinto et al., 2020) |
| EW-8B non-RBD anti Spike | Neg Control | (Huang et al., 2020) |
| EW-9C non-RBD anti Spike | Neg Control | (Huang et al., 2020) |
| FJ-1C anti NTD | Neg Control | (Huang et al., 2020) |

Supplementary Figure 1 A, B) Three MAbs or Nanobody-Fc reagents of 15 tested specific for

RBD failed to cross-link red cells but could be developed with an anti IgG reagent. Antibodies

were titrated from 500 ng/well to 1 ng/well in 50 µL, 1:40 red cells were added in 50 µL,

followed by 100 ng/well IH4-RBD in 50 µL, and incubated for 1 hour.  The labelled red cells

were then resuspended, and either 50 µL PBS (L hand plates), or Sigma Clone GG5 anti human

IgG 1:100 in 50 µL (R hand plates). Red cells were allowed to settle for one hour, the plate

tilted for 30s and photographed.

**A** **Comparison of HAT Results**
$R^2 = 0.975$

Slope = 0.94 (95% CI 0.92 - 0.96)

Suggests second set has tendency
to detect ~1 doubling dilution (DD) lower titres

230/232 (99%) were within 1 DD

**B** Titration in HAT by doubling dilution (Repeat)

| | Critical | Severe | Mild | HCW | Sepsis | Healthy |
|---|---|---|---|---|---|---|
| N samples | 32 | 62 | 39 | 20 | 54 | 25 |
| N donors | 24 | 48 | 32 | | 43 | |

Donors were grouped according to clinical criteria; HCW = Front Line Health Care Workers; Sepsis = Samples with patients with Sepsis prior to Covid-19 pandemic; Healthy = Healthy volunteers prior to Covid-19; DD 1 = 1:40. Actual Titre = 20 x 2^DD.

**C**

| | HAT +ve | HAT -ve | Total | Fraction |
|---|---|---|---|---|
| Siemens +ve | 108 | 5 | 113 | 0.96 |
| Siemens -ve | 16 | 24 | 40 | 0.40 |
| Total | 124 | 29 | 153 | 0.81 |
| Fraction | 0.87 | 0.83 | 0.74 | |

| P value and statistical significance | |
|---|---|
| Test | Fisher's exact test |
| P value | <0.0001 |
| P value summary | **** |
| One- or two-sided | Two-sided |

Sensitivity (Sn) HAT 81%, Sn Siemens 74%
HAT still more sensitive than Siemens

Specificity 100% for HAT in these samples

Supplementary Figure 2. A) The 232 samples from figure 5 in the main paper were titrated a

second time 34 days after the first measurement, as described for figure 4 (Methods). The

values for the end point doubling dilution were compared and a correlation coefficient, and

slope calculated (Prism v8).

B) The collection included 32 samples from 24 Critical patients, 62 samples from 48 Severe,

39 samples from 32 Mild, 20 single samples from health care workers (HCW), 54 samples from

43 patients with unrelated sepsis in the pre-Covid-19 era, 25 samples from healthy unexposed

controls. Median is shown.

C) Comparison to Siemens Result (anti RBD) with HAT Titre by Doubling Dilution for 153

samples from Critical, Severe, Mild and HCW PCR+ve donors. The sensitivity of the HAT in this

repeat was 81%, v 86% in the first test.

Supplementary Table 2. Fifty-two samples from 24 donors who were sampled repeatedly

during the first five days in hospital; assay repeated 34 days after the measurements in Table

1. Sixteen of 24 showed a rise in titre.

| No | Case | Day 1 | 2 | 3 | 4 | 5 |
|----|------|-------|---|------|---|--------|
| 1 | C2 | | | 40 | | 160 |
| 2 | C6 | | | 0 | | 80 |
| 3 | C7 | 0 | | | | 0 |
| 4 | C9 | 0 | | | | 1280 |
| 5 | C10 | 160 | | 320 | | |
| 6 | C23 | 0 | | 80 | | 320 |
| 7 | S5 | 40 | | 40 | | |
| 8 | S6 | 1280 | | 2560 | | 2560 |
| 9 | S7 | 80 | | | | 1280 |
| 10 | S12 | 320 | | 640 | | |
| 11 | S13 | 0 | | 0 | | 160 |
| 12 | S14 | | | 640 | | 1280 |
| 13 | S17 | | | 1280 | | 1280 |
| 14 | S20 | 80 | | 320 | | |
| 15 | S31 | 0 | | | | 640 |
| 16 | S41 | 640 | | 1280 | | |
| 17 | S43 | | | 40 | | 80 |
| 18 | S48 | | | 1280 | | 1280 |
| 19 | M9 | | | 40 | | 160 |
| 20 | M11 | 0 | | 0 | | 0 |
| 21 | M13 | | | 0 | | 0 |
| 22 | M14 | | | 163840 | | 163840 |
| 23 | M25 | 40 | | | | 320 |
| 24 | M30 | | | 160 | | 160 |

**DNA sequence of codon optimised cDNA encoding IH4-RBD**

ATGGGATGGTCATGTATCATCCTTTTTCTAGTAGCAACTGCAACCGGTGTTCATAGCCAGGTC
CAGCTGCAAGAGTCTGGCGGAGGATCTGTTCAGGCTGGCGGAAGCCTGAGACTGAGCTGTGT
GGCCAGCGGCTACACCGATAGCACATACTGCGTCGGCTGGTTCAGACAGGCCCCTGGCAAAG
AGAGAGAGGGCGTCGCCAGAATCAACACCATCAGCGGCAGACCTTGGTACGCCGACTCTGTG
AAGGGCAGATTCACAATCAGCCAGGACAACAGCAAGAACACCGTGTTTCTGCAGATGAACA
GCCTGAAGCCAGAGGACACCGCCATCTACTACTGCACCCTGACCACCGCCAACAGCAGAGGC
TTTTGTTCCGGCGGCTACAACTACAAAGGCCAGGGCACCCAAGTGACCGTGTCTAGCGCGTC
GACCGGCTCTGGCGGCAGCGGCAACATCACCAATCTGTGCCCTTTCGGCGAGGTGTTCAACG
CCACCAGATTTGCCAGCGTGTACGCCTGGAACCGGAAGAGAATCAGCAACTGCGTGGCCGAC
TACAGCGTGCTGTACAATAGCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACC
AAGCTGAACGACCTGTGCTTCACCAATGTGTACGCCGACAGCTTCGTGATCAGAGGCGACGA
AGTTCGGCAGATCGCTCCTGGACAGACAGGCAAGATCGCCGATTACAACTACAAGCTGCCCG
ACGACTTCACCGGCTGCGTGATCGCCTGGAATAGCAACAACCTGGACAGCAAAGTCGGCGGC
AACTACAACTACCTGTACCGGCTGTTCCGGAAGTCCAACCTGAAGCCTTTCGAGCGGGACAT
CAGCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAATGGCGTGGAAGGCTTCAACTGCT
ACTTCCCACTGCAGTCCTACGGCTTTCAGCCTACAAACGGCGTGGGCTACCAGCCTTATAGAG
TGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCCTGCTACCGTGTGCGGCCCTAAAAAACACC
ATCACCACCACCATTGA